Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for ultrafiltration, hemoperfusion, and hemofiltration, effective May 15, 2026. Here's what billing teams need to do.
CMS updated its policy governing these three renal replacement and blood purification therapies. The policy does not list specific CPT or HCPCS codes in the available data—but if your team bills for ultrafiltration, hemoperfusion, or hemofiltration under Medicare, this change affects your medical necessity documentation and claim submission. Review your charge capture and documentation workflows before May 15, 2026.
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Ultrafiltration, Hemoperfusion and Hemofiltration |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | 2026-05-15 |
| Impact Level | High |
| Specialties Affected | Nephrology, Critical Care, Interventional Nephrology, Hospital Outpatient |
| Key Action | Audit documentation and charge capture for ultrafiltration, hemoperfusion, and hemofiltration claims before May 15, 2026 |
CMS Ultrafiltration, Hemoperfusion, and Hemofiltration Coverage Criteria and Medical Necessity Requirements 2026
The Centers for Medicare & Medicaid Services ultrafiltration, hemoperfusion, and hemofiltration coverage policy governs three distinct but related therapies. Each has its own clinical indications, and CMS treats them separately when evaluating medical necessity. Understanding the distinctions matters for your billing team—conflating these therapies on claims is a fast path to a claim denial.
Ultrafiltration removes excess fluid from the blood. It's used primarily in patients with acute decompensated heart failure who are refractory to diuretics. CMS coverage for ultrafiltration turns on whether the patient has a documented failure to respond to pharmacologic fluid management.
Hemoperfusion passes blood through an adsorbent material—typically activated charcoal or resin—to remove toxins. It's most commonly indicated for drug overdose or poisoning when the offending substance is adsorbable. Medical necessity documentation for hemoperfusion must establish the specific toxin, its concentration, and why standard supportive care is insufficient.
Hemofiltration removes fluid and solutes via convection rather than diffusion. It's used in acute kidney injury, often in the ICU setting as continuous renal replacement therapy (CRRT). CMS requires documentation that conventional intermittent hemodialysis is not tolerated or is contraindicated.
All three therapies share a common thread in this coverage policy: CMS requires clear medical necessity documentation. That means the treating physician's notes must connect the patient's clinical condition to the specific therapy chosen—not just indicate that a renal or cardiac problem exists.
Prior authorization requirements vary by Medicare Administrative Contractor. Your MAC may impose additional local coverage determination criteria on top of this national policy. Check your MAC's LCD before assuming this national policy is the only standard you need to meet. If you're unsure which MAC governs your claims, talk to your compliance officer before the effective date of May 15, 2026.
Reimbursement for these services depends on both correct procedure code selection and supporting diagnosis codes. CMS will not reimburse a claim where the procedure and diagnosis don't form a coherent clinical narrative.
CMS Ultrafiltration, Hemoperfusion, and Hemofiltration Exclusions and Non-Covered Indications
CMS does not cover these therapies when used outside their established indications. Ultrafiltration billed for patients who haven't failed diuretic therapy is a coverage issue—not just a documentation one. The same logic applies to hemoperfusion when the substance involved isn't adsorbable, or when hemofiltration is used as a convenience alternative to standard hemodialysis in a patient who could tolerate conventional treatment.
Experimental or investigational uses are not covered. If your facility is using hemoperfusion for cytokine removal in sepsis—a growing practice—understand that CMS has not broadly established this as a covered indication. Some MACs have issued LCDs on sepsis-related hemoperfusion. Check your local coverage determination before billing.
Any therapy billed without a supporting diagnosis that meets medical necessity criteria will be denied. Document the failed alternatives, the clinical rationale, and the specific therapy chosen. That documentation is your defense on audit.
Coverage Indications at a Glance
The policy data provided does not include a detailed indication-by-indication breakdown. The table below reflects CMS's established coverage framework for these therapies based on the policy title and known CMS standards. Confirm specific criteria against your MAC's LCD and the full policy text at app.payerpolicy.org/p/cms/55-v1.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Ultrafiltration for acute decompensated heart failure refractory to diuretics | Covered when medical necessity criteria are met | Codes not listed in available policy data | Documentation must establish diuretic failure |
| Hemoperfusion for drug overdose or poisoning with adsorbable substance | Covered when medical necessity criteria are met | Codes not listed in available policy data | Toxin type and concentration must be documented |
| Hemofiltration / CRRT for acute kidney injury with contraindication to intermittent hemodialysis | Covered when medical necessity criteria are met | Codes not listed in available policy data | Must document intolerance or contraindication to conventional dialysis |
| Hemoperfusion for cytokine removal in sepsis | Not established as covered; check your MAC's LCD | Codes not listed in available policy data | Some MACs have issued LCDs—verify before billing |
| Any therapy used outside established clinical indications | Not covered | N/A | Claim denial risk is high |
CMS Ultrafiltration, Hemoperfusion, and Hemofiltration Billing Guidelines and Action Items 2026
The available policy data does not include the line-by-line changes from this modification. That limits how granular these action items can be. But the structure of this coverage policy—and the history of how CMS handles modifications to complex renal and cardiac therapies—points to several concrete steps your billing team should take before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull and review the full policy text before May 15, 2026. The available data flags this as a modified policy. You need to read the actual policy document at app.payerpolicy.org/p/cms/55-v1. to understand exactly what changed. Don't wait. A modification to medical necessity criteria or documentation requirements can flip clean claims into denials overnight. |
| 2 | Check your MAC's LCD for each of the three therapies. This national policy sets the floor. Your Medicare Administrative Contractor may have issued—or may be updating—a local coverage determination with more specific criteria. Ultrafiltration billing, in particular, has been an area of active MAC scrutiny over the past two years. |
| 3 | Audit your documentation templates. Your physicians' procedure notes must explicitly address medical necessity for the specific therapy billed. Generic "renal failure" or "fluid overload" documentation doesn't cut it. Each therapy requires a different clinical narrative—failed diuretics for ultrafiltration, specific toxin exposure for hemoperfusion, contraindication to conventional dialysis for hemofiltration. |
| 4 | Verify your charge capture maps to the correct procedure codes. The policy does not list specific CPT or HCPCS codes in the available data. That means you need to confirm which codes your facility currently uses for these therapies and ensure they still map to covered indications under the modified policy. If you're unsure, contact your billing consultant before the effective date. |
| 5 | Review any prior authorization workflows tied to these services. If your MAC requires prior auth for any of these therapies, confirm that your authorization requests align with the updated coverage policy criteria. An authorization obtained under old criteria may not protect you if the policy criteria changed. |
| 6 | Flag high-volume accounts for a targeted claims review. If your facility performs ultrafiltration, hemoperfusion, or hemofiltration at any significant volume, pull a 90-day lookback on paid claims for these services. Identify any patterns that could signal exposure under the modified criteria. |
If you run a high-volume nephrology or critical care program, loop in your compliance officer now. Policy modifications to complex renal therapies have audit implications—not just prospective billing implications.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Ultrafiltration, Hemoperfusion, and Hemofiltration Under This Policy
The policy data provided for this modification does not include specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for a CMS policy modification at this stage—detailed code tables sometimes appear in the final published version rather than the initial modification notice.
Do not attempt to infer codes from the policy title alone. Ultrafiltration, hemoperfusion, and hemofiltration each have distinct procedure codes, and billing the wrong one—even for a procedure that is clinically covered—creates claim denial exposure.
What to do: Pull the full policy document at https://app.payerpolicy.org/p/cms/55-v1 and review the code list directly. Cross-reference against your current charge description master (CDM) to identify any codes that need to be added, retired, or reassigned.
When the full code list is available, your team should organize codes by coverage status:
- Covered codes when medical necessity criteria are met
- Codes subject to frequency or setting limitations
- Codes considered experimental or non-covered under this policy
Your compliance officer or billing consultant should validate the final code list against your CDM before May 15, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.